TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $428,896 | -41.1% | 47,975 | +1.2% | 0.00% | 0.0% |
| Q2 2023 | $728,156 | -22.9% | 47,406 | +12.8% | 0.00% | 0.0% |
| Q1 2023 | $944,962 | +6.9% | 42,017 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $883,617 | -17.3% | 42,017 | -3.1% | 0.00% | -50.0% |
| Q3 2022 | $1,068,069 | -50.4% | 43,347 | -51.3% | 0.00% | -60.0% |
| Q2 2022 | $2,155,000 | +256.8% | 88,982 | +279.9% | 0.01% | +400.0% |
| Q1 2022 | $604,000 | -15.5% | 23,422 | +1.8% | 0.00% | 0.0% |
| Q4 2021 | $715,000 | +26.5% | 23,013 | -1.2% | 0.00% | 0.0% |
| Q3 2021 | $565,000 | +65.7% | 23,304 | -0.1% | 0.00% | 0.0% |
| Q2 2021 | $341,000 | -40.6% | 23,324 | +1.4% | 0.00% | 0.0% |
| Q1 2021 | $574,000 | -4.3% | 23,007 | +4.4% | 0.00% | 0.0% |
| Q4 2020 | $600,000 | – | 22,030 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |